|
Details of the monoclonal antibodies in the 'MCW Melanoma Cocktail'. |
|||
| Marker |
Clone |
Source |
*Final Dilution in the cocktail |
|
|
|||
| MART-1 |
M2-7C10 |
Signet Laboratories, Inc. Dedham, MA |
1:500 |
| Melan-A |
A103 |
Dako Corporation, Carpinteria, CA |
1:100 |
| Tyrosinase |
T311 |
Novocastra Laboratories Ltd Newcastle upon Tyne, UK |
1:50 |
|
* Optimum dilution for each antibody was standardized individually for that batch of antibodies with the sections of known melanoma positive control. The standardized dilution was achieved as final titer in the cocktail by adding 20 μl MART-1, 100 μl Melan-A, and 200 μl Tyrosinase to 9.68 ml of DAKO Antibody diluent (Dako Corporation, Carpinteria, CA). | |||
Shidham et al. BMC Cancer 2003 3:15 doi:10.1186/1471-2407-3-15 |
|||